Medpace Holdings, Inc. $MEDP Shares Bought by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. significantly increased its stake in Medpace Holdings by 675.8% in the first quarter, acquiring 105,807 additional shares, bringing its total ownership to approximately 121,464 shares.
• Analysts have mixed opinions on Medpace, with Mizuho raising its price target to $510.00, while UBS Group downgraded the stock to a "sell" rating, reflecting a general divergence in market sentiment.
• Medpace reported a 14.2% year-over-year revenue growth for the most recent quarter, with earnings per share of $3.10, exceeding analysts’ expectations by $0.10.

Jacobs Levy Equity Management Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 675.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 121,464 shares of the company's stock after purchasing an additional 105,807 shares during the period. Jacobs Levy Equity Management Inc. owned 0.42% of Medpace worth $37,009,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. Brooklyn Investment Group increased its position in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. increased its position in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares during the last quarter. Colonial Trust Co SC increased its position in shares of Medpace by 150.0% in the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after purchasing an additional 105 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Medpace in the 1st quarter worth about $60,000. Finally, Assetmark Inc. increased its position in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the transaction, the chief executive officer owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Jesse J. Geiger sold 41,801 shares of the company's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the completion of the transaction, the president owned 36,503 shares of the company's stock, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock worth $74,111,427 in the last quarter. 20.30% of the stock is currently owned by corporate insiders.

Medpace Trading Down 1.3%

MEDP traded down $6.50 during trading on Tuesday, reaching $485.59. 450,200 shares of the company were exchanged, compared to its average volume of 445,165. The stock has a market cap of $13.64 billion, a P/E ratio of 36.10, a PEG ratio of 3.06 and a beta of 1.44. The firm has a 50 day moving average of $419.54 and a 200 day moving average of $346.21. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period in the prior year, the business earned $2.75 EPS. The firm's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of several research analyst reports. Rothschild & Co Redburn downgraded shares of Medpace from a "buy" rating to a "neutral" rating and boosted their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Mizuho boosted their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Barclays lifted their price target on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Finally, TD Cowen reaffirmed a "sell" rating and issued a $366.00 price target (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Reduce" and a consensus price target of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.